In this study we selected a low dose of GE2, based on prior research in rats (60) and the original study using this conjugate (59), after guidance from the Novo Nordisk team (BF, JD, BY)
It is not approved by any regulatory authority and has not been evaluated for safety or efficacy in humans
PCOS-Specific Challenges Long-term management of PCOS goes beyond weight loss - it involves tackling the specific risks and complications associated with the condition
Important: If your medication was clear when you first received it and has changed color, or if it contains floating particles or looks cloudy, do not inject it
In 2023 the firm abandoned development of lotiglipron after trial participants showed elevated liver enzymes, and the same year discontinued a twice-daily danuglipron dosing regime after almost three quarters of treated patients experienced nausea, while almost a half developed vomiting and a quarter diarrhoea